Lexicon Pharmaceuticals Announces CMO Retirement and Appointment
Ticker: LXRX · Form: 8-K · Filed: Apr 29, 2024
Sentiment: neutral
Topics: executive-change, personnel
TL;DR
Lexicon's CMO is retiring June 30, Dr. Johnson takes over immediately.
AI Summary
Lexicon Pharmaceuticals, Inc. announced on April 24, 2024, the retirement of its Chief Medical Officer, Dr. Jeffrey L. Cleary, effective June 30, 2024. Dr. Cleary will transition to a consulting role until December 31, 2024. The company has appointed Dr. Tamara A. P. Johnson as the new Chief Medical Officer, effective immediately.
Why It Matters
This filing details a significant leadership change in the medical department, which could impact the company's drug development pipeline and regulatory strategies.
Risk Assessment
Risk Level: medium — Changes in key executive positions, especially the Chief Medical Officer, can introduce uncertainty regarding strategic direction and execution in drug development.
Key Players & Entities
- Lexicon Pharmaceuticals, Inc. (company) — Registrant
- Dr. Jeffrey L. Cleary (person) — Retiring Chief Medical Officer
- June 30, 2024 (date) — Effective retirement date for Dr. Cleary
- December 31, 2024 (date) — End of Dr. Cleary's consulting role
- Dr. Tamara A. P. Johnson (person) — New Chief Medical Officer
- April 24, 2024 (date) — Date of the earliest event reported
FAQ
Who is the new Chief Medical Officer at Lexicon Pharmaceuticals?
Dr. Tamara A. P. Johnson has been appointed as the new Chief Medical Officer.
When is Dr. Jeffrey L. Cleary's retirement effective?
Dr. Cleary's retirement is effective June 30, 2024.
Will Dr. Cleary remain involved with the company after retirement?
Yes, Dr. Cleary will transition to a consulting role until December 31, 2024.
What is the filing date for this 8-K report?
The filing date is April 29, 2024, reporting the earliest event as April 24, 2024.
What is Lexicon Pharmaceuticals' principal executive office address?
The address is 2445 Technology Forest Blvd., 11th Floor, The Woodlands, Texas 77381.
Filing Stats: 432 words · 2 min read · ~1 pages · Grade level 11.9 · Accepted 2024-04-29 09:00:27
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 LXRX The Nasdaq Global Select Market
Filing Documents
- form8-kcoatsretirement.htm (8-K) — 17KB
- 0001062822-24-000020.txt ( ) — 18KB
Signatures
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Lexicon Pharmaceuticals, Inc. Date April 29, 2024 By s Brian T. Crum Brian T. Crum Senior Vice President and General Counsel